{"id":"NCT01783678","sponsor":"Gilead Sciences","briefTitle":"A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults","officialTitle":"A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01","primaryCompletion":"2014-04","completion":"2014-07","firstPosted":"2013-02-05","resultsPosted":"2015-04-30","lastUpdate":"2015-04-30"},"enrollment":275,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C","Human Immunodeficiency Virus"],"interventions":[{"type":"DRUG","name":"Sofosbuvir","otherNames":["SovaldiÂ®","GS-7977","PSI-7977"]},{"type":"DRUG","name":"RBV","otherNames":[]}],"arms":[{"label":"Genotype 2 treatment-naive","type":"EXPERIMENTAL"},{"label":"Genotype 2/3 treatment-experienced","type":"EXPERIMENTAL"},{"label":"Genotype 1/3/4 treatment-naive","type":"EXPERIMENTAL"}],"summary":"This is an Open-label Phase 3 study in adults with chronic genotypes 1, 2, 3, and 4 HCV infection who are co-infected with HIV-1.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"Genotype 2 Treatment-naive","deltaMin":89.5,"sd":null},{"arm":"All Genotype 1 Treatment-naive","deltaMin":84.8,"sd":null},{"arm":"Genotype 1a Treatment-naive","deltaMin":84,"sd":null},{"arm":"Genotype 1b Treatment-naive","deltaMin":90.9,"sd":null},{"arm":"Genotype 2 Treatment-experienced","deltaMin":83.3,"sd":null},{"arm":"Genotype 3 Treatment-naive","deltaMin":91.2,"sd":null},{"arm":"Genotype 3 Treatment-experienced","deltaMin":85.7,"sd":null},{"arm":"Genotype 4 Treatment-naive","deltaMin":83.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":11},"locations":{"siteCount":24,"countries":["Australia","France","Germany","Italy","Spain","United Kingdom"]},"refs":{"pmids":["25659285","25583164"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["Fatigue","Asthenia","Insomnia","Headache","Nausea"]}}